Search Results

Walgreens helps raise more than $6 million for The Leukemia & Lymphoma Society (LLS) and Susan G. Komen to Advance Cancer Research and Increase Access to Care

Join us in thanking Walgreens stores and customers across the country for raising over $6 million for LLS and Susan G. Komen during their spring campaign. Donations made at checkout at more than 9,000 U.S. Walgreens locations will be split evenly between the two organizations.

During this multi-year partnership, Walgreens has helped to donate more than $25 million by 2024 to advance research for tough-to-treat cancers and increase equitable access to care.

Hodgkin Lymphoma Subtypes

The World Health Organization (WHO) divides Hodgkin lymphoma into two main subtypes. They are:

Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma (NHL)

• Is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines or skin. In some cases, NHL involves bone marrow and blood.
• Isn't just one disease–it's actually a diverse group of blood cancers that all arise from lymphocytes (white blood cells that are part of the immune system).
• Lymphoma cells may develop in just one place or in many sites in the body.
• NHL has many different subtypes which are either indolent (slow-growing) or aggressive (fast-grow

Hodgkin Lymphoma Staging

Doctors use physical examinations, imaging tests, blood test and, sometimes, bone marrow tests to determine the extent of the disease.  This determination is called "staging."  Staging provides important information for treatment planning.

Staging for Hodgkin lymphoma is based on the Lugano classification, which is derived from the Ann Arbor staging system.

Childhood Hodgkin Lymphoma

Because of new and better therapies, cancer survival rates for children have improved dramatically during the last several decades. Scientists continue to search for the causes of childhood lymphoma so they can develop better treatments with less toxic side effects.

Next-Generation Targeted Therapy in Mantle Cell Lymphoma and Transformed Follicular Lymphoma

The field of cancer treatment has made remarkable progress with the adoption of targeted therapy; however, small molecule drugs have limitations such as drug resistance and off-target toxicities. To overcome these challenges, we have developed an innovative approach that enhances the potency and precision of small molecule drugs. Our cutting-edge high-precision pretargeted nanoparticles can deliver potent triple inhibitors that effectively combat drug-resistant mantle cell lymphoma and dual proteolysis targeting chimeras (PROTACs) for treatment of transformed follicular lymphoma.

Adolescent & Young Adult Cancer Awareness Week: Free Support & Financial Resources from The Leukemia & Lymphoma Society for Blood Cancer Patients, Survivors, Families & Caregivers

** The following article highlights free resources and programs that might be of particular interest to the young adult community; these are also available to all blood cancer patients, including the families and caregivers of adolescents with a blood cancer. We encourage parents/guardians of minors (up to age 18) to request a free copy of the “Caring for Kids And Adolescents With Blood Cancer” workbook by calling 800-955-4572 and to learn more below about ways LLS can help. 

Developing Novel Immunotherapies for Challenging Lymphomas

This team science program from Washington University will develop new immunotherapy treatments for patients with hard to treat or incurable lymphomas. The team includes physicians and scientists who have developed new ideas in the laboratory for immune-based treatment, and will translate these to clinical trial testing. These include engineered natural kill cells, healthy donors T cell engineered to attack a T cell lymphoma, and lymphoma-patient specific mutations as vaccine targets.

Living with Hodgkin Lymphoma

Hodgkin Lymphoma (HL)

Follicular Lymphoma (FL)

Spotlight On Hodgkin Lymphoma

Booklet Updates - Lymphoma

Childhood Non-Hodgkin Lymphoma

Because of new and better therapies, cancer survival rates for children have improved dramatically during the last several decades. Scientists continue to search for the causes of childhood lymphoma so they can develop better treatments with less toxic side effects.         

Analysis and therapeutic targeting of the immune regulatory and ubiquitination pathways in Anaplastic Large Cell Lymphoma and Hodgkin Lymphoma

My lab is focused on the immune regulatory mechanisms and ubiquitin-dependent machinery in lymphoma. We have established multiple high-throughput screening technologies and animal models to rapidly and accurately identify critical pathways that are suitable for targeted therapy and immunotherapy. Gaining insight into the pathological roles of these pathways can lead to improved understandings of the molecular circuitry that drives lymphoma pathogenesis and provide novel therapeutic strategies.

Translational Discovery in Peripheral T-Cell Lymphomas

Peripheral T-cell lymphomas (PTCLs) are poorly understood and patients with PTCL are underserved by current therapies. The most common subtypes (among >20) are PTCL-not otherwise specific (NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALK- ALCL). Rational treatment strategies for these lymphomas are lacking, largely due to the insufficient characterization of PTCL pathobiology and historic paucity of faithful models.

The Follicular Lymphoma Foundation Joins Forces With The Leukemia & Lymphoma Society to Bring Hope to Those Living With Follicular Lymphoma

Working for The Leukemia & Lymphoma Society

Hodgkin Lymphoma 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

 

Lymphoma Research Funded by LLS

Information for Patients with Aggressive Lymphomas